17.5 C
New York
Wednesday, May 25, 2022

Theramex Supports IOF SCOPE 2021 Recommendations and Calls for Action to Eliminate Disparities in Osteoporosis Care Across Europe

- Advertisement -
- Advertisement -

LONDON, March 22, 2022–(BUSINESS WIRE)–The International Osteoporosis Foundation (IOF) has published its “Scorecard for Osteoporosis in Europe” (SCOPE) 2021. This report, which describes the epidemiology, burden and management of osteoporosis in each of the 27 countries of the European Union, Switzerland and the United Kingdom reveals some disturbing data:

  • 1 in 3 women will suffer an osteoporotic fracture in her life.

  • An unacceptable treatment gap exists: 71% of women eligible for osteoporosis treatment do not receive treatment despite the high cost of fractures and affordable medications.

  • Osteoporosis and the 4.3 million fragility fractures it causes each year cost European health systems more than €56 billion each year, with only 3% spent on medical treatment, according to 2019 data.

  • By 2034, the number of fragility fractures is expected to increase by 25%.

  • Nearly a quarter of a million deaths occur in Europe each year as a direct result of fractures of the hip or spine.

Osteoporosis is not inevitable and can be treated. Women lose approximately 50% of their trabecular bone and 30% of their cortical bone throughout their lives, with just under half lost in the first 10 years after menopause. The evaluation of osteoporosis through bone mineral density screening is a fundamental pillar for adequate treatment.

IOF calls for a Europe-wide strategy for coordinated osteoporosis care (including the establishment of adequate screening services), together with national strategies, to reduce the number of debilitating fragility fractures that have a serious impact on the lives of people. people, society and the health system. .

In partnership with the IOF and the National Osteoporosis Societies, Theramex is committed to raising awareness of the burden of osteoporosis and closing the unacceptable treatment gap that exists in Europe in terms of education, assessment and treatment of women, thus improving treatment results. For more information, see the full SCOPE report, which you can read here.

About Theramex

Theramex is a leading global specialty pharmaceutical company committed to empowering women and their health. With a broad portfolio of innovative and established brands in the areas of contraception, fertility, menopause and osteoporosis, Theramex supports women at all stages of life. We strive to listen to women, understand and meet their needs, and provide health solutions that help improve their quality of life. Our vision is to be a lifelong partner for women and the healthcare professionals who treat them, providing effective, patient-centered solutions that care for and support women at every stage of life.

The source language in which the original text is published is the official and authorized version. Translations will be included for better understanding. Only the version in the language that was originally published is legally valid. Therefore, compare the translations with the original language version of the publication.

View the original version on businesswire.com: https://www.businesswire.com/news/home/20220321005531/en/

contacts

Jesus Lopez | Associate Director, Communication and Digital | [email protected]

Source link

- Advertisement -

New Articles